71.34
price up icon2.93%   2.03
after-market 시간 외 거래: 72.56 1.22 +1.71%
loading
전일 마감가:
$69.31
열려 있는:
$69.12
하루 거래량:
1.15M
Relative Volume:
0.71
시가총액:
$7.66B
수익:
$628.56M
순이익/손실:
$141.82M
주가수익비율:
56.62
EPS:
1.26
순현금흐름:
$142.60M
1주 성능:
-3.58%
1개월 성능:
-0.47%
6개월 성능:
+42.77%
1년 성능:
+126.05%
1일 변동 폭
Value
$68.52
$71.57
1주일 범위
Value
$68.52
$75.95
52주 변동 폭
Value
$29.42
$117.33

코르셉트 테라퓨틱스 Stock (CORT) Company Profile

Name
명칭
Corcept Therapeutics Inc
Name
전화
650.688.8803
Name
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Name
직원
500
Name
트위터
Name
다음 수익 날짜
2025-02-17
Name
최신 SEC 제출 서류
Name
CORT's Discussions on Twitter

CORT을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CORT
Corcept Therapeutics Inc
71.34 7.66B 628.56M 141.82M 142.60M 1.26
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2023-11-06 업그레이드 Truist Hold → Buy
2023-04-11 개시 SVB Securities Market Perform
2023-04-04 개시 Piper Sandler Overweight
2023-02-15 다운그레이드 Jefferies Buy → Hold
2022-08-01 다운그레이드 Truist Buy → Hold
2022-07-27 업그레이드 Jefferies Hold → Buy
2022-06-27 재개 Canaccord Genuity Buy
2022-02-02 개시 Canaccord Genuity Buy
2022-01-28 개시 Truist Buy
2020-08-05 다운그레이드 Jefferies Buy → Hold
2019-09-24 개시 Jefferies Buy
2019-09-06 개시 H.C. Wainwright Buy
2019-02-04 다운그레이드 B. Riley FBR Buy → Neutral
2018-08-10 재확인 Stifel Hold
2018-05-31 다운그레이드 Stifel Buy → Hold
2018-03-09 개시 B. Riley FBR, Inc. Buy
2017-08-31 개시 Stifel Buy
2017-02-02 개시 Ladenburg Thalmann Buy
2015-04-21 개시 FBR Capital Outperform
2014-01-13 다운그레이드 Stifel Buy → Hold
2013-08-09 다운그레이드 Janney Buy → Neutral
2013-08-09 다운그레이드 Ladenburg Thalmann Buy → Neutral
2012-02-21 재확인 JMP Securities Mkt Outperform
2010-01-06 업그레이드 Ladenburg Thalmann Neutral → Buy
2008-07-17 개시 Rodman & Renshaw Mkt Outperform
2007-06-21 업그레이드 Punk, Ziegel & Co Mkt Perform → Accumulate
모두보기

코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스

pulisher
Jun 16, 2025

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much TodayCorcept Therapeutics (NASDAQ:CORT) - Benzinga

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept reports annual meeting outcomes By Investing.com - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Corcept May 2025 slides: Revenue target of $900-950M amid pipeline advances - Investing.com Canada

Jun 16, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

Corcept Therapeutics director Daniel Swisher sells $155k in stock By Investing.com - Investing.com Canada

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Swisher Daniel N JR Sells 2,200 Shares of Corcept Therapeutics Inc (CORT) - GuruFocus

Jun 12, 2025
pulisher
Jun 11, 2025

Relacorilant delays ovarian cancer disease progression: Trial data - Rare Cancer News

Jun 11, 2025
pulisher
Jun 06, 2025

Corcept claims survival benefit in ALS despite missed endpoint - PharmaLive

Jun 06, 2025
pulisher
Jun 06, 2025

Mixed Phase II results for Corcept’s dazucorilant - The Pharma Letter

Jun 06, 2025
pulisher
Jun 06, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Purchased by Public Employees Retirement System of Ohio - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting - afp.com

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept plots future for ALS drug that flunked Phase 2, citing survival analysis - Endpoints News

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept's mid-stage ALS study fails (CORT:NASDAQ) - Seeking Alpha

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in P - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics Says Its ALS Drug Candidate Fails to Meet Primary Goal - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics (CORT) Reports Promising Survival Data in A - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting | CORT Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept Therapeutics (CORT) Reports Promising Survival Data in ALS Study | CORT Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 04, 2025

Corcept therapeutics officer Joseph Lyon sells shares worth $390,218 - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? - Yahoo Finance

Jun 04, 2025
pulisher
Jun 04, 2025

H.C. Wainwright Reaffirms Corcept Therapeutics Incorporated (CORT)’s $145 Price Target, Maintains Buy Rating - Insider Monkey

Jun 04, 2025
pulisher
Jun 03, 2025

ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer - Yahoo Finance

Jun 03, 2025
pulisher
Jun 03, 2025

Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday - Yahoo

Jun 03, 2025
pulisher
Jun 02, 2025

Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatment - Yahoo Finance

Jun 02, 2025
pulisher
Jun 02, 2025

Relacorilant shows promise for ovarian cancer treatment By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept Therapeutics (CORT) Shows Positive Phase 3 Trial Results for Ovarian Cancer Treatment | CORT Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept shares rise on positive Phase 3 trial results By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept shares rise on positive Phase 3 trial results - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Relacorilant shows promise for ovarian cancer treatment - Investing.com

Jun 02, 2025
pulisher
Jun 02, 2025

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - Business Wire

Jun 02, 2025
pulisher
Jun 02, 2025

Zacks Research Issues Pessimistic Outlook for CORT Earnings - Defense World

Jun 02, 2025
pulisher
May 30, 2025

Here's How Much $1000 Invested In Corcept Therapeutics 5 Years Ago Would Be Worth Today - Benzinga

May 30, 2025
pulisher
May 30, 2025

Zacks Research Has Negative Outlook for CORT Q2 Earnings - Defense World

May 30, 2025
pulisher
May 30, 2025

Equities Analysts Offer Predictions for CORT Q1 Earnings - Defense World

May 30, 2025
pulisher
May 29, 2025

Bank of America Corp DE Cuts Stock Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

May 29, 2025
pulisher
May 28, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Nuveen Asset Management LLC - Defense World

May 28, 2025
pulisher
May 23, 2025

Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Lessened by Cetera Investment Advisers - Defense World

May 23, 2025
pulisher
May 22, 2025

Abortion Drugs Market Deep Research and Growth in Future Scope - openPR.com

May 22, 2025
pulisher
May 21, 2025

Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) - FinancialContent

May 21, 2025
pulisher
May 21, 2025

Director, Oncology Patient Support OperationsRedwood CityCorcept Therapeutics - Ladders

May 21, 2025
pulisher
May 21, 2025

Deutsche Bank AG Buys 24,051 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World

May 21, 2025
pulisher
May 19, 2025

CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed - Yahoo Finance

May 19, 2025
pulisher
May 18, 2025

Critical Review: Kaya (OTCMKTS:KAYS) vs. Corcept Therapeutics (NASDAQ:CORT) - Defense World

May 18, 2025
pulisher
May 15, 2025

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Cushing's Syndrome Market Growth Drivers and Industry Insights - openPR.com

May 15, 2025
pulisher
May 14, 2025

Corcept Therapeutics (NASDAQ:CORT) Downgraded to “Hold” Rating by StockNews.com - Defense World

May 14, 2025
pulisher
May 12, 2025

Here's How Much You Would Have Made Owning Corcept Therapeutics Stock In The Last 5 Years - Benzinga

May 12, 2025
pulisher
May 12, 2025

Corcept Therapeutics (NASDAQ:CORT) Is Posting Promising Earnings But The Good News Doesn’t Stop There - Yahoo Finance

May 12, 2025

코르셉트 테라퓨틱스 (CORT) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
자본화:     |  볼륨(24시간):